Diffuse Large B-cell Lymphoma Therapeutics Market - 2021-
Description
Diffuse Large B-cell Lymphoma Therapeutics Market Overview:
The Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4,107.50 million in 2021 and is anticipated to reach by , at a CAGR of 0.075 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Diffuse Large B-cell Lymphoma Therapeutics Market.
This report delivers a comprehensive overview of the Diffuse Large B-cell Lymphoma Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diffuse Large B-cell Lymphoma Therapeutics Market. The Diffuse Large B-cell Lymphoma Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
Diffuse Large B-cell Lymphoma Therapeutics Market Scope:
By Drug Type
• Immuno and Targeted Drugs
• Others-Combination Drugs
By Route of Administration
• Intravenous Route
By End-user
• Hospitals
• Cancer Centers
• Others
Key Players
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Celltrion
• Karyopharm Therapeutics
• Kite Pharma
• MorphoSys AG
• AbbVie
• CTI BioPharma
• Seagen Inc
• TG Therapeutics(LIST NOT EXHAUSTIVE)
Major Highlights
This report delivers a comprehensive overview of the Diffuse Large B-cell Lymphoma Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diffuse Large B-cell Lymphoma Therapeutics Market. The Diffuse Large B-cell Lymphoma Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Diffuse Large B-cell Lymphoma Therapeutics Market was valued at USD 4,107.50 million in 2021 and is anticipated to reach by , at a CAGR of 0.075 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Diffuse Large B-cell Lymphoma Therapeutics Market.
This report delivers a comprehensive overview of the Diffuse Large B-cell Lymphoma Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diffuse Large B-cell Lymphoma Therapeutics Market. The Diffuse Large B-cell Lymphoma Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
Diffuse Large B-cell Lymphoma Therapeutics Market Scope:
By Drug Type
• Immuno and Targeted Drugs
• Others-Combination Drugs
By Route of Administration
• Intravenous Route
By End-user
• Hospitals
• Cancer Centers
• Others
Key Players
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Celltrion
• Karyopharm Therapeutics
• Kite Pharma
• MorphoSys AG
• AbbVie
• CTI BioPharma
• Seagen Inc
• TG Therapeutics(LIST NOT EXHAUSTIVE)
Major Highlights
This report delivers a comprehensive overview of the Diffuse Large B-cell Lymphoma Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Diffuse Large B-cell Lymphoma Therapeutics Market. The Diffuse Large B-cell Lymphoma Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
217 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Market Definition and Overview
- 3. Executive Summary
- 3.1. Market Snippet by Drug Type
- 3.2. Market Snippet by Route of Administration
- 3.3. Market Snippet by End-user
- 3.4. Market Snippet by Region
- 4. Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing preference for targeted therapies
- 4.1.2. Restraints:
- 4.1.2.1. High cost of treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Patent Analysis
- 5.3. Pipeline Analysis
- 5.4. Epidemiology
- 5.5. Supply Chain Analysis
- 5.6. Pricing Analysis
- 5.7. Regulatory Analysis
- 5.8. Unmet Needs
- 6. COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Drug Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 7.1.2. Market Attractiveness Index, By Drug Type
- 7.2. Immuno and Targeted Drugs*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.2.3. Rituximab (Rituxan)
- 7.2.4. Polatuzumab vedotin-piiq (Polivy)
- 7.2.5. Tisagenlecleucel (Kymriah)
- 7.2.6. Tafasitamab-cxix (Monjuvi)
- 7.2.7. Selinexor (XPOVIO)
- 7.2.8. Axicabtagene ciloleucel (Yescarta)
- 7.2.9. Others (Pembrolizumab (Keytruda), Ibrutinib)
- 7.3. Others-Combination Drugs
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
- 8.1.2. Market Attractiveness Index, By Route of Administration Segment
- 8.2. Intravenous Route*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.2.3. Oral
- 9. By End-user
- 9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
- 9.1.2. Market Attractiveness Index, By End-user Segment
- 9.2. Hospitals
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.3. Cancer Centers
- 9.4. Others
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. U.K.
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
- 11. Competitive Landscape
- 11.1. Key Developments and Strategies
- 11.2. Company Share Analysis
- 11.3. Product Benchmarking
- 11.4. Key Companies to Watch
- 11.5. Company with disruptive technology
- 11.6. Start Up Companies
- 12. Company Profiles
- 12.1. F. Hoffmann-La Roche Ltd*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
- 12.2. Novartis AG
- 12.3. Celltrion
- 12.4. Karyopharm Therapeutics
- 12.5. Kite Pharma
- 12.6. MorphoSys AG
- 12.7. AbbVie
- 12.8. CTI BioPharma
- 12.9. Seagen Inc
- 12.10. TG Therapeutics(*LIST NOT EXHAUSTIVE)
- 13. DataM Intelligence
- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
